CN108324803A - Solid beverage of auxiliary hyperglycemic and preparation method thereof - Google Patents
Solid beverage of auxiliary hyperglycemic and preparation method thereof Download PDFInfo
- Publication number
- CN108324803A CN108324803A CN201810245750.3A CN201810245750A CN108324803A CN 108324803 A CN108324803 A CN 108324803A CN 201810245750 A CN201810245750 A CN 201810245750A CN 108324803 A CN108324803 A CN 108324803A
- Authority
- CN
- China
- Prior art keywords
- extract
- solid beverage
- green
- preparation
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000007787 solid Substances 0.000 title claims abstract description 75
- 235000013361 beverage Nutrition 0.000 title claims abstract description 74
- 238000002360 preparation method Methods 0.000 title claims abstract description 20
- 230000003345 hyperglycaemic effect Effects 0.000 title abstract description 28
- 239000000284 extract Substances 0.000 claims abstract description 90
- 244000269722 Thea sinensis Species 0.000 claims abstract description 50
- 235000013616 tea Nutrition 0.000 claims abstract description 28
- 235000009508 confectionery Nutrition 0.000 claims abstract description 26
- 241000124033 Salix Species 0.000 claims abstract description 25
- 235000009569 green tea Nutrition 0.000 claims abstract description 23
- 235000013761 grape skin extract Nutrition 0.000 claims abstract description 21
- 235000020688 green tea extract Nutrition 0.000 claims abstract description 15
- 229940094952 green tea extract Drugs 0.000 claims abstract description 15
- 239000004615 ingredient Substances 0.000 claims abstract description 9
- 238000012545 processing Methods 0.000 claims description 32
- 238000001694 spray drying Methods 0.000 claims description 22
- 150000004676 glycans Chemical class 0.000 claims description 6
- 229920001282 polysaccharide Polymers 0.000 claims description 6
- 239000005017 polysaccharide Substances 0.000 claims description 6
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims description 5
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical group C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims description 5
- 235000021283 resveratrol Nutrition 0.000 claims description 5
- 229940016667 resveratrol Drugs 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 4
- LXBIFEVIBLOUGU-UHFFFAOYSA-N Deoxymannojirimycin Natural products OCC1NCC(O)C(O)C1O LXBIFEVIBLOUGU-UHFFFAOYSA-N 0.000 claims description 3
- YWPVROCHNBYFTP-UHFFFAOYSA-N Rubusoside Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC1OC(CO)C(O)C(O)C1O YWPVROCHNBYFTP-UHFFFAOYSA-N 0.000 claims description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 claims description 3
- 239000005030 aluminium foil Substances 0.000 claims description 3
- 229930003944 flavone Natural products 0.000 claims description 3
- 150000002212 flavone derivatives Chemical class 0.000 claims description 3
- 235000011949 flavones Nutrition 0.000 claims description 3
- YWPVROCHNBYFTP-OSHKXICASA-N rubusoside Chemical group O([C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YWPVROCHNBYFTP-OSHKXICASA-N 0.000 claims description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 2
- 238000012856 packing Methods 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 238000010298 pulverizing process Methods 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims 1
- 208000011580 syndromic disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 44
- 230000000694 effects Effects 0.000 abstract description 34
- 235000013305 food Nutrition 0.000 abstract description 8
- 241000196324 Embryophyta Species 0.000 abstract description 6
- 238000005516 engineering process Methods 0.000 abstract description 6
- 230000010534 mechanism of action Effects 0.000 abstract description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 78
- 206010012601 diabetes mellitus Diseases 0.000 description 76
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 34
- 229940079593 drug Drugs 0.000 description 31
- 239000008280 blood Substances 0.000 description 29
- 210000004369 blood Anatomy 0.000 description 29
- 239000008103 glucose Substances 0.000 description 28
- 210000000496 pancreas Anatomy 0.000 description 28
- 241000699670 Mus sp. Species 0.000 description 26
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 21
- 102000004877 Insulin Human genes 0.000 description 17
- 108090001061 Insulin Proteins 0.000 description 17
- 229940125396 insulin Drugs 0.000 description 17
- 240000000249 Morus alba Species 0.000 description 14
- 235000008708 Morus alba Nutrition 0.000 description 14
- 238000002156 mixing Methods 0.000 description 13
- 210000002966 serum Anatomy 0.000 description 13
- 238000004806 packaging method and process Methods 0.000 description 12
- 238000003304 gavage Methods 0.000 description 11
- 230000006872 improvement Effects 0.000 description 11
- 210000004185 liver Anatomy 0.000 description 11
- 210000005229 liver cell Anatomy 0.000 description 9
- 210000004153 islets of langerhan Anatomy 0.000 description 8
- 230000002218 hypoglycaemic effect Effects 0.000 description 7
- 230000002757 inflammatory effect Effects 0.000 description 7
- 230000003914 insulin secretion Effects 0.000 description 7
- 150000002632 lipids Chemical class 0.000 description 7
- 102000017011 Glycated Hemoglobin A Human genes 0.000 description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 210000003934 vacuole Anatomy 0.000 description 6
- 102000004889 Interleukin-6 Human genes 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 239000000306 component Substances 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 235000021588 free fatty acids Nutrition 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 210000003462 vein Anatomy 0.000 description 5
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 4
- 108010014663 Glycated Hemoglobin A Proteins 0.000 description 4
- 206010019708 Hepatic steatosis Diseases 0.000 description 4
- 206010022489 Insulin Resistance Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 210000000805 cytoplasm Anatomy 0.000 description 4
- 230000036541 health Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000004940 nucleus Anatomy 0.000 description 4
- 238000007410 oral glucose tolerance test Methods 0.000 description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- FRWNAQDBODEVAL-VMPITWQZSA-N (5e)-5-[(4-nitrophenyl)methylidene]-2-sulfanylidene-1,3-thiazolidin-4-one Chemical compound C1=CC([N+](=O)[O-])=CC=C1\C=C\1C(=O)NC(=S)S/1 FRWNAQDBODEVAL-VMPITWQZSA-N 0.000 description 3
- QNMKGMUGYVWVFQ-UHFFFAOYSA-N 2alpha-Hydroxyursolic acid Natural products CC12CC(O)C(O)C(C)(C)C1CCC1(C)C2CC=C2C3C(C)C(C)(C)CCC3(C(O)=O)CCC21C QNMKGMUGYVWVFQ-UHFFFAOYSA-N 0.000 description 3
- 206010003694 Atrophy Diseases 0.000 description 3
- 206010011224 Cough Diseases 0.000 description 3
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 3
- 108010028144 alpha-Glucosidases Proteins 0.000 description 3
- 230000037444 atrophy Effects 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 235000012000 cholesterol Nutrition 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 235000008216 herbs Nutrition 0.000 description 3
- 239000007928 intraperitoneal injection Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229940123208 Biguanide Drugs 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010018473 Glycosuria Diseases 0.000 description 2
- 102000015779 HDL Lipoproteins Human genes 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- ZSJLQEPLLKMAKR-UHFFFAOYSA-N Streptozotocin Natural products O=NN(C)C(=O)NC1C(O)OC(CO)C(O)C1O ZSJLQEPLLKMAKR-UHFFFAOYSA-N 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 229930013930 alkaloid Natural products 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 150000004283 biguanides Chemical class 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 108091005995 glycated hemoglobin Proteins 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 230000001788 irregular Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000001151 other effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000837 restrainer Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000007863 steatosis Effects 0.000 description 2
- 231100000240 steatosis hepatitis Toxicity 0.000 description 2
- 229960001052 streptozocin Drugs 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000050051 Chelone glabra Species 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000007926 Craterellus fallax Nutrition 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 240000007175 Datura inoxia Species 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 241000892865 Heros Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010021703 Indifference Diseases 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 235000011034 Rubus glaucus Nutrition 0.000 description 1
- 244000235659 Rubus idaeus Species 0.000 description 1
- 235000009122 Rubus idaeus Nutrition 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000003064 anti-oxidating effect Effects 0.000 description 1
- -1 anticancer Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 238000000889 atomisation Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000021258 carbohydrate absorption Nutrition 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 238000007446 glucose tolerance test Methods 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 150000008131 glucosides Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 238000002703 mutagenesis Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000005426 pharmaceutical component Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- PJANXHGTPQOBST-UHFFFAOYSA-N stilbene Chemical class C=1C=CC=CC=1C=CC1=CC=CC=C1 PJANXHGTPQOBST-UHFFFAOYSA-N 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/82—Theaceae (Tea family), e.g. camellia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/52—Juglandaceae (Walnut family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/87—Vitaceae or Ampelidaceae (Vine or Grape family), e.g. wine grapes, muscadine or peppervine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Non-Alcoholic Beverages (AREA)
Abstract
The invention belongs to food technology fields, and in particular to a kind of solid beverage of auxiliary hyperglycemic and preparation method thereof.The solid beverage includes the ingredient of following mass percentage：Green-tea extract 20.0~50.0%；Loquat-leaf extract 2.0~30.0%；Grape skin extract 1.0~10.0%；Sweet tea extract 2.0~10.0%；Mulberry-leaf extract 5.0~20.0%；Blue or green money willow extract 5.0~20.0%.Active components of plants in the solid beverage has collaboration facilitation, has significant auxiliary hyperglycemic effect, and the solid beverage is easy the utilization that is absorbed by the body, with good compatibility, the mechanism of action of its auxiliary hyperglycemic is clear, and safety is good, without any side effects；In addition, it with green tea taste, mouthfeel is easy to be received, and complication and side effect caused by taking Western medicine for a long time are avoided.
Description
Technical field
The invention belongs to food technology fields, and in particular to a kind of solid beverage of auxiliary hyperglycemic and preparation method thereof.
Background technology
Diabetes (Diabetes Mellitus, DM) are to threaten one of the principal disease of human life and health, at present it
It has become after tumour and cardiovascular and cerebrovascular disease, it is the third-largest to seriously threaten the chronic disease of human health, once suffering from, need
Life-long therapy.
Currently, the hypoglycemic drug used in therapeutic treatment diabetes is various in style, insulin preparation and its substitute are main
It is to be directed to type 1 diabetes, diabetes B also needs insulin injection based on oral hypoglycemic drug when serious.Orally-taken blood sugar reducing Western medicine
Mainly there are three categories：Sulfonylureas (Sulphonylureas), biguanides (Biguanides) and alpha-glucosidase restrainer (α-
Glucosidase Inhibitors), though Western medicine can efficiently control blood glucose, a variety of adverse reactions can be generated, side effect is big,
It should not be used as long-term prevention and treatment.Traditional traditional Chinese medicine course for the treatment of is long, slow curative effect, and mouthfeel is bitter, it is difficult to drink, patient
It tends not to adhere to for a long time.Modern study finds that blood sugar reducing component mainly has terpene, flavonoids, polysaccharide, life in natural plants
Alkaloids class, Coumarins, steroid, Polyphenols, saponins and unsaturated fatty acids etc., these active constituents largely exist
In medicinal plant, partly for contained by food or medical and edible dual purpose plant.And just there is the culture of " integration of drinking and medicinal herbs " in China from ancient times, passes
The culture of health preserving and TCM Culture of system are the resources that China is inexhaustible, nexhaustible.Chinese medicine thinks that integration of drinking and medicinal herbs, medicine is eaten
It mutually uses, there is no stringent boundary between medicine and food, and medicinal and edible plant active constituent is easy to be absorbed and utilized for human body, have very
Good compatibility, mouthfeel are also easy to be received.
Tealeaves have it is long drink history, because it contains there are many active skull cap components, there is anti-oxidant, anticancer, drop courage
Sterol, reducing blood lipid inhibit the effects that blood pressure raising, excitor nerve.It is civil in China and Japan, often there is thick old green tea treatment glycosuria
The experience of disease, and there is numerous studies report to confirm that green tea has effect of lowering blood sugar.Loguat leaf, cold nature is bitterly, cough-relieving, clearly
Lung and stomach, lowering the adverse-rising QI to resolve phlegm, record in go through edition Chinese Pharmacopoeia for tcm clinical practice use.Loguat leaf not only has removing heat from the lung to relieve cough harmonizing stomach and lowering adverse Qi
The effect of, and have the effects that apparent hypoglycemic, inhibition cancer cell multiplication, anti-inflammatory, anti-oxidation stress.Recent study table
Bright, the plant extracts containing Corosolic acid (Corosolic acid) can stimulate the glucose transport channel of cell membrane, increase
Strong utilization of the cell to glucose, and then blood-sugar content is reduced, this effect is similar to Hypoglycemic Action Due To Insulin mechanism.According to《China
Chinese medicinal herbal is wanted》It records, blue or green money willow bark, leaf have clearing heat and detoxicating, and millet paste sweetness that this leaf bubbles out is moistened, and is promoted the production of body fluid to quench thirst
And other effects.Modern research shows that Qingqian Willow leaf and its extract (polysaccharide and general flavone) have preferable hypoglycemic effect.From ancient times
Since mulberry leaf just the Application to the Chinese medical herbs as treatment diabetes early has note in clinic in many classic medical works in China
It carries.《Compendium of Materia Medica》It records：Mulberry leaf are hand, the positive bright medicine of foot, and improving eyesight long hair is only quenched one's thirst.Modern pharmacological studies have shown that polyhydroxy
Alkaloid 1-DNJ (1-deoxojirimycin, DNJ) is one of mulberry leaf active ingredient, its structure is similar to day
So sugar, the emulative inhibition alpha-glucosidase of energy, has significant hypoglycemic effect.Mainly there is active material in grape pomace
Anthocyan, resveratrol and flavonoids.Resveratrol is a kind of non-flavonoids polyphenolic substance containing stilbene class formation, colourless
Acicular crystal has anticancer, antibacterial, anti-oxidant, Green Tea Extract, prevents the various biologicals such as heart disease and anti-mutagenesis activity and medicine
Reason acts on.The mass data obtained from zoopery shows that resveratrol can improve diabetic animal body by number of mechanisms
Interior hyperglycemia, insulin β cell damages and Insulin resistance.It is recorded according to Guangxi Chinese medicine standard, Sweet tea (sweet tea
Leaf raspberry) there is the effect of heat-clearing and fire-reducing, moistening lung and production of body fluid, cough-relieving apophlegmatic.Sweet tea glucoside extract is for hyperglycemic rat hypoglycemic
The result of study of effect shows that the sweetness agent classification extract of doses can reduce normal mouse blood glucose level, for by
The gluconeogenesis of examination animal, which has, significantly inhibits effect.It can also reduce that serum glycerine three is cruel and the content of cholesterol simultaneously.
Invention content
It is an object of the invention to overcome the above-mentioned deficiency of the prior art, provide a kind of auxiliary hyperglycemic solid beverage and
Preparation method, it is intended to solve the undesirable technical problem of existing assistant hypoglycemic beverage effect.
For achieving the above object, the technical solution adopted by the present invention is as follows：
One aspect of the present invention provides a kind of solid beverage, is the solid in terms of 100% by the gross mass of the solid beverage
Beverage includes the ingredient of following mass percentage：
Another aspect of the present invention provides a kind of preparation method of above-mentioned solid beverage, includes the following steps：
There is provided the green-tea extract, loquat-leaf extract, grape skin extract, sweet tea extract, mulberry-leaf extract and
Blue or green money willow extract；
By the green-tea extract, loquat-leaf extract, grape skin extract, sweet tea extract, mulberry-leaf extract and blueness
After money willow extract carries out mixed processing, the first spray drying is carried out, the solid beverage is obtained.
Solid beverage provided by the invention is optimized as raw material using the plant extracts of 6 kinds of medicine-food two-purposes
It is formulated, the active components of plants in the formula has collaboration facilitation, has significant auxiliary hyperglycemic effect, and the solid
Beverage is easy the utilization that is absorbed by the body, and has good compatibility, and the mechanism of action of auxiliary hyperglycemic is clear, and safety is good,
It is without any side effects；In addition, it with green tea taste, mouthfeel is easy to be received, avoid concurrent caused by taking Western medicine for a long time
Disease and side effect.
Description of the drawings
Fig. 1 is 30 days diabetes B mouse liver HE dyeing knots of solid beverage continuous gavage in the embodiment of the present invention 12
Fruit is schemed；Wherein, A to F be followed successively by respectively normal group, diabetes group, low dose group, middle dose group, high dose group and positive drug
Group；Black arrow show central vein, and green arrow show liver rope, and red arrow show liver cell nuclear；
Fig. 2 is 30 days diabetes B mice pancreatic HE dyeing knots of solid beverage continuous gavage in the embodiment of the present invention 12
Fruit is schemed；Wherein, A to F be followed successively by respectively normal group, diabetes group, low dose group, middle dose group, high dose group and positive drug
Group；Black arrow show pancreas islet.
Specific implementation mode
In order to make technical problems, technical solutions and advantageous effects to be solved by the present invention be more clearly understood, below in conjunction with
Embodiment, the present invention will be described in further detail.It should be appreciated that specific embodiment described herein is only used to explain
The present invention is not intended to limit the present invention.
On the one hand, an embodiment of the present invention provides a kind of solid beverages, with the gross mass of the solid beverage for 100%
Meter, the solid beverage includes the ingredient of following mass percentage：
Solid beverage provided in an embodiment of the present invention is optimized as raw material using the plant extracts of 6 kinds of medicine-food two-purposes
The formula of design, the active components of plants in the formula have collaboration facilitation, have significant auxiliary hyperglycemic effect, and
The solid beverage is easy the utilization that is absorbed by the body, and has good compatibility, the mechanism of action of auxiliary hyperglycemic is clear, safety
Property is good, without any side effects；In addition, it with green tea taste, mouthfeel is easy to be received, and is avoided caused by taking Western medicine for a long time
Complication and side effect.
Further, the solid beverage includes the ingredient of following mass percentage：
Solid beverage auxiliary hyperglycemic effect under the content is best.
Further, in the solid beverage, the main active of the loquat-leaf extract is Corosolic acid；It is described
The main active of grape skin extract is resveratrol；The main active of the sweet tea extract is Rubusoside and sweet tea
Tea polysaccharide；The main active of the mulberry-leaf extract is 1-DNJ；The main work of the blue or green money willow extract
Property ingredient be blue or green money willow polysaccharide and general flavone.
On the other hand, the embodiment of the present invention additionally provides the preparation method of above-mentioned solid beverage, includes the following steps：
S01：The green-tea extract, loquat-leaf extract, grape skin extract, sweet tea extract, mulberry leaf extraction are provided
Object and blue or green money willow extract；
S02：By the green-tea extract, loquat-leaf extract, grape skin extract, sweet tea extract, mulberry-leaf extract
After carrying out mixed processing with blue or green money willow extract, the first spray drying is carried out, the solid beverage is obtained.
The solid beverage that above-mentioned preparation method obtains has significant auxiliary hyperglycemic effect, and the solid beverage is easy quilt
Absorption of human body utilizes, and has good compatibility, and have green tea taste, and mouthfeel is easy to be received, and avoids long-term use west
Complication caused by medicine and side effect, the solid beverage is convenient, is easy to carry about with one, economical and practical, applied widely.
The crushing technology of high pressure microjet is to be combined high-tension apparatus and micro passage reaction device, is answered using microchannel plate
Super-pressure (such as 310MPa) that is small, reaching can reach quickly mixing, homogeneous and emulsification under cavitation and effect of impact
And other effects, the problems such as nano particle of formation can be effectively improved material water soluble characteristic, dissolution rate, bioavilability, operation letter
The plurality of advantages such as just, expense cost is low.Therefore, in the above-mentioned steps S02 of the embodiment of the present invention, the mixed processing is first high
Microjet pulverization process is pressed, 6 kinds of ingredients in crushing technology homogeneous mixing formula are handled using high pressure microjet, solid drink can be increased
Material formula brew, improves mouthfeel, and increase reconstitutes stability etc..Further, the condition of first spray drying includes：Into
103-107 DEG C of air temperature, 65-75 DEG C of temperature of outgoing air, 48-52 DEG C of tower wall temperature；Atomizer rotating speed 17000r/min.In the atomization
Under device speed conditions, spray effect is best；Within the said temperature range, make the drying effect for finally obtaining solid beverage best.
General green-tea extract, loquat-leaf extract, grape skin extract, sweet tea extract, mulberry-leaf extract and green money
Willow extract can directly be bought, but in order to make the mouthfeel of the solid beverage be easier to be received, can utilize high pressure microjet
Treatment technology prepares green-tea extract, maintains the original nutrition of green tea, pharmaceutical component to the maximum extent in this way, green tea is made to extract
Object has very strong superficial attractive forces and affinity, the solid organic traits such as fragrance and good suspension stability, be particularly easy to by
Gastrointestinal disturbances absorb.It is 0 calorie to extract obtained Rubusoside, high sugariness, the perfect generation sugar in palatable and health care ground.
Specifically, the preparation method of the green-tea extract includes：
T01：Collect green tea；
T02：After green tea water-removing, defibrination, the processing of the second high pressure microjet is carried out, comminuting matter is obtained；
T03：After the comminuting matter centrifugal filtration, the second spray drying is carried out, the green-tea extract is obtained.
Further, in step T03, the rotating speed of the centrifugal filtration is 3000-5000r/min.Under the speed conditions
Centrifugal effect is best.
Further, in step T03, the condition of second spray drying includes：106-110 DEG C of inlet air temperature, air draft
63-67 DEG C of temperature, 48-52 DEG C of tower wall temperature；Atomizer rotating speed 17000r/min.Under the conditions of the atomizer rotating speed, spraying effect
Fruit is best；Within the said temperature range, make the drying effect of the green-tea extract of preparation best.
Further, further include the steps that In Aluminium Foil Packing after the step of described first is spray-dried.
That is the preferred steps of the preparation method of the solid beverage of the auxiliary hyperglycemic of the embodiment of the present invention are：
Step 1：Using spring tea fresh leaf after rain as raw material, water-removing, defibrination, then through high-pressure jet receive atomizer crush, mistake
Filter, spray drying are made；
Step 2：It weighs, functional component, major ingredient and corrigent is subjected to accurate weighing, it is spare；
Step 3：Sample after weighing is added into appropriate water, is mixed evenly, upper high-pressure jet receives atomizer homogeneous；
Step 4：Spray drying；
Step 5：Packaging of aluminium foil bag.
The embodiment of the present invention prepare solid beverage can not influence be formulated efficacy exertion in the case of can be arbitrary
Suitable product form is selected, the above-mentioned product type referred to is not limited to, when specifically taking, the piece of original new drug can be made
Agent, capsule, oral solution etc..
The present invention successively carried out test of many times, and it is further detailed to invention progress as reference now to lift A partial experiment result
Thin description, is described in detail with reference to specific embodiment.
Embodiment 1
A kind of solid beverage of auxiliary hyperglycemic, the solid beverage are that the green tea for being 36.0% by weight percent extracts
Object, 24.0% loquat-leaf extract, 4.0% grape skin extract, 6.0% sweet tea extract, 10.0% mulberry leaf carry
Take object and 20.0% blue or green money willow extract, through mixing, high-pressure jet receive Crushing of Ultrafine uniformly, spray drying, packaging be made.
Embodiment 2
A kind of solid beverage of auxiliary hyperglycemic, the solid beverage are that the green tea for being 37.0% by weight percent extracts
Object, 20.0% loquat-leaf extract, 1.0% grape skin extract, 2.0% sweet tea extract, 20.0% mulberry leaf carry
Take object and 20.0% blue or green money willow extract, through mixing, high-pressure jet receive Crushing of Ultrafine uniformly, spray drying, packaging be made.
Embodiment 3
A kind of solid beverage of auxiliary hyperglycemic, the solid beverage are that the green tea for being 50.0% by weight percent extracts
Object, 8.0% loquat-leaf extract, 7.0% grape skin extract, 10.0% sweet tea extract, the extraction of 5.0% mulberry leaf
Object and 20.0% blue or green money willow extract, through mixing, high-pressure jet receive Crushing of Ultrafine uniformly, spray drying, packaging be made.
Embodiment 4
A kind of solid beverage of auxiliary hyperglycemic, the solid beverage are that the green tea for being 36.0% by weight percent extracts
Object, 30.0% loquat-leaf extract, 10.0% grape skin extract, 3.0% sweet tea extract, 5.0% mulberry leaf carry
Take object and 16.0% blue or green money willow extract, through mixing, high-pressure jet receive Crushing of Ultrafine uniformly, spray drying, packaging be made.
Embodiment 5
A kind of solid beverage of auxiliary hyperglycemic, the solid beverage are that the green tea for being 50.0% by weight percent extracts
Object, 4.0% loquat-leaf extract, 6.0% grape skin extract, 5.0% sweet tea extract, the extraction of 20.0% mulberry leaf
Object and 15.0% blue or green money willow extract, through mixing, high-pressure jet receive Crushing of Ultrafine uniformly, spray drying, packaging be made.
Embodiment 6
A kind of solid beverage of auxiliary hyperglycemic, the solid beverage are that the green tea for being 24.0% by weight percent extracts
Object, 24.0% loquat-leaf extract, 10.0% grape skin extract, 10.0% sweet tea extract, 18.0% mulberry leaf
Extract and 14.0% blue or green money willow extract, through mixing, high-pressure jet receive Crushing of Ultrafine uniformly, spray drying, packaging be made.
Embodiment 7
A kind of solid beverage of auxiliary hyperglycemic, the solid beverage are that the green tea for being 30.0% by weight percent extracts
Object, 30.0% loquat-leaf extract, 1.0% grape skin extract, 10.0% sweet tea extract, 19.0% mulberry leaf carry
Take object and 10.0% blue or green money willow extract, through mixing, high-pressure jet receive Crushing of Ultrafine uniformly, spray drying, packaging be made.
Embodiment 8
A kind of solid beverage of auxiliary hyperglycemic, the solid beverage are that the green tea for being 40.0% by weight percent extracts
Object, 30.0% loquat-leaf extract, 3.0% grape skin extract, 2.0% sweet tea extract, 15.0% mulberry leaf carry
Take object and 10.0% blue or green money willow extract, through mixing, high-pressure jet receive Crushing of Ultrafine uniformly, spray drying, packaging be made.
Embodiment 9
A kind of solid beverage of auxiliary hyperglycemic, the solid beverage are that the green tea for being 35.0% by weight percent extracts
Object, 30.0% loquat-leaf extract, 10.0% grape skin extract, 10.0% sweet tea extract, 10.0% mulberry leaf
Extract and 5.0% blue or green money willow extract, through mixing, high-pressure jet receive Crushing of Ultrafine uniformly, spray drying, packaging be made.
Embodiment 10
A kind of solid beverage of auxiliary hyperglycemic, the solid beverage are that the green tea for being 25.0% by weight percent extracts
Object, 30.0% loquat-leaf extract, 10.0% grape skin extract, 10.0% sweet tea extract, 20.0% mulberry leaf
Extract and 5.0% blue or green money willow extract, through mixing, high-pressure jet receive Crushing of Ultrafine uniformly, spray drying, packaging be made.
Embodiment 11
A kind of solid beverage of auxiliary hyperglycemic, the solid beverage are that the green tea for being 31.0% by weight percent extracts
Object, 26.8% loquat-leaf extract, 16.7% blue or green money willow extract, 14.1% mulberry-leaf extract, 6.4% Grape Skin
Extract and 5.0% sweet tea extract, through mixing, high-pressure jet receive Crushing of Ultrafine uniformly, spray drying, packaging be made.
Embodiment 12
One, auxiliary hyperglycemic verification test
1. experimental animal and grouping：Healthy C57BL/6J heros mouse 48,5-6 week old are dynamic purchased from the experiment of Beijing dimension tonneau China
Object Technology Co., Ltd..Every four mouse are divided into a cage, and totally 12 cage, free water are ingested, 22 ± 1 DEG C, 12:12 day and night recycle
Environment in adapt to one week.
2. model foundation and grouping：It is fed 4 weeks with high lipid food plus streptozotocin (STZ) intraperitoneal injection 2 types of structure is sugared
Disease model is urinated, normal group mouse feeding is common to maintain feed, and equivalent citrate buffer is injected intraperitoneally.It is latter STZ has been injected
The blood glucose value of week detection mouse blood sugar value, mouse is more than that 11mmol/L is considered as diabetes B mouse.
After being grouped according to mouse blood sugar value, with the solid beverage of embodiment 11 to mouse with it is basic, normal, high (50,100,
200mg/kg B.W.) dosage gavage, while (soup minister is good for auxiliary hyperglycemic piece, By-Health, 200mg/kg again with positive drug
B.W. gavage, the normal solvent (physiological saline) for organizing mouse and diabetes group intragastric administration on mice same volume) are carried out to respective sets mouse.
Mice group mark respectively normal group, diabetes group, low dose group, middle dose group, high dose group and positive drug group：
Normal group (physiological saline of same volume)
Diabetes group (physiological saline of same volume)
Low dose group (50mg/kg B.W.)
Middle dose group (100mg/kg B.W.)
High dose group (200mg/kg B.W.)
Positive drug group (200mg/kg B.W.).
3. index determining：Record mouse weight is primary weekly, and the variation of record mouse feed is twice.Measure fasting blood-glucose, mouth
Take glucose tolerance test (OGTT), intraperitoneal injection insulin tolerance tests (IPITT), Fasting insulin experiment, glucose
Promote insulin secretion experiment (GSIS), blood lipids index, glycosylated hemoglobin and inflammatory factor.
4. data statistics：As a result average value ± SEM is used to indicate, statistical analysis is all made of 20 softwares of SPSS Statistics
It carries out.P<0.05 is considered significant difference statistically.
Two, experimental result
1. the influence pair diabetes B mouse weight
As shown in table 1, the original body mass difference of mouse is not notable, average weight ranging from 23.58-24.90g.With it is normal
Group is compared, and diabetic mice group weight is substantially reduced, and weight differences are notable.After continuous medicine-filling is handled 1 month, diabetes group is small
Mouse average weight (28.77 ± 0.34g) is still significantly lower than normal group mouse (32.82 ± 0.53g).And through 11 sample of embodiment
The mouse weight of processing then has different degrees of increase, weight to increase with dosage and increase compared with diabetic mice, and agent is presented
Graded effect, and the mouse weight of various dose processing is all remarkably higher than diabetes group mouse.
Influence of 1 sample treatment of table to diabetes B mouse weight
Note：There were significant differences for expression of the right shoulder of each column without identical lowercase, P<0.05.
2. the influence pair diabetes B mouse food ration
By record mouse in the gavage stage to the Expenditure Levels of feed, as shown in table 2, normal group (13.15 ±
0.39kcal), diabetic mice group (13.19 ± 0.28kcal), 11 low dosage processing group of embodiment (12.95 ±
0.24kcal), middle dosage processing group (13.76 ± 0.56kcal), high dose processing group (12.87 ± 0.36kcal) and positive drug
The daily equal indifference of food ration of object processing group (13.84 ± 0.29kcal) mouse.
Influence of 2 sample treatment of table to diabetes B mouse per Day feeding amount
Note：There were significant differences for expression of the right shoulder of each column without identical lowercase, P<0.05.
3. the influence pair diabetes B mouse fasting blood-glucose
Before gavage processing, continuous gavage 15 days and when continuous gavage 30 days measure fasting blood-glucose.As shown in table 3, glycosuria
The blood glucose of sick mouse is apparently higher than normal group mouse, and before gavage each blood glucose in diabetic mice without significant difference.
After continuous gavage 15 days, normal mouse fasting blood sugar of organizing is 6.64 ± 0.25mmol/L, and diabetes group mouse is empty
Abdomen blood glucose is 15.52 ± 0.12mmol/L, and diabetes group mouse fasting blood-glucose is still significantly higher than normal group mouse.And embodiment 11
It is substantially reduced diabetes B mouse group with positive drug group fasting blood-glucose, and the blood glucose value of various dose processing group shows agent
Measure dependence.The fasting blood-glucose of wherein high dose processing group mouse is substantially less than positive drug processing group mouse.
Fasting blood-glucose after successive administration 30 days, 11 low dose group of embodiment, middle dose group, high dose group and positive drug group
Fasting blood sugar compared with 15 days before also have a degree of decline, and show doses rely on effect.Wherein embodiment 11
The blood sugar decreasing effect of sample high dose group processing is better than positive drug group, significant difference.
Influence of 3 sample treatment of table to diabetes B mouse fasting blood-glucose
Note：There were significant differences for expression of the right shoulder of each column without identical lowercase, P<0.05.
4. the influence pair diabetes B mouse islets element
As shown in table 4, the Fasting insulin level of diabetes group mouse is significantly lower than normal group mouse.Through various dose reality
After applying 11 sample of example and positive drug processing, low dose group, middle dose group, high dose group and positive drug group fasting insulin water
It is flat to be dramatically increased compared with diabetes group, and the processing of sample high dose promotes the effect of insulin secretion to be better than positive drug processing.
After glucose gavage 15min, diabetes group mouse islets element concentration is significantly lower than normal group mouse.And through it is low,
Middle and high dose sample processing, mouse blood insulin concentration increase, and show dose-effect relationship, and high dose sample treatment group
The effect of insulin secretion is promoted to be significantly better than positive drug group.
The influence of 4 sample treatment of table 30 days to mouse blood insulin
Note：There were significant differences for expression of the right shoulder of each column without identical lowercase, P<0.05.
5. the influence pair diabetes B Mouse oral glucose tolerance (OGTT)
The results are shown in Table 5 for oral glucose tolerance test.After intragastric administration on mice glucose, the blood glucose of all groups of mouse exists
Maximum value is risen to when 30min, and downward trend is then presented.Compared with normally group mouse, the oral Portugal of diabetes group mouse
Grape sugar tolerance is obviously damaged, and area under the curve obviously increases, than normally organizing increase by 90.34%.Through low dosage, middle dosage, height
After dose sample and positive drug processing, area under the curve reduces compared with diabetes group, is increased compared with normal group, different agent
It measures sample and doses dependence is presented to the improvement of oral glucose tolerance, and the processing of middle and high dose sample is resistance to sugar
The improvement of amount is better than positive drug, significant difference.
5 successive administration of table handles the influence to mouse OGTT in 30 days
Note：There were significant differences for expression of the right shoulder of each column without identical lowercase, P<0.05.
6. the influence pair diabetes B mouse peritoneal insulin injection tolerance
Insulin tolerance tests are injected intraperitoneally, and the results are shown in Table 6, and each group mouse is with the dosage abdominal cavity of 1U/kg B.W.
After insulin injection, blood glucose value minimizes after 60min, then shows the trend of rising.Diabetes group mouse 30,
60, the equal highest of ratio of the blood glucose of 90 and 120min and 0min blood glucose and it is apparently higher than normal group mouse, and through sample and the positive
After drug-treated, the insulin tolerance of mouse is significantly improved, from area under the curve it can be seen that on dosage is gradual
It rises, the blood glucose value decline after mouse peritoneal insulin injection is more notable, i.e., insulin sensitivity is higher.It can from 6 data of table
Go out, high dose sample treatment improves the best results of insulin sensitivity, and even better than positive drug is handled, significant difference.
6 successive administration of table handles the influence to mouse IPITT in 30 days
Note：There were significant differences for expression of the right shoulder of each column without identical lowercase, P<0.05.
7. the influence pair diabetes B lipid of mice index
As shown in table 7, triglycerides, cholesterol in diabetes B mice serum, low close compared with normally group mouse
Degree lipoprotein and free fatty all dramatically increase, and high-density lipoprotein significantly reduces.Continuously locate by sample and positive drug
After 30 days, triglycerides, cholesterol, low-density lipoprotein and free fatty in mice serum all significantly reduce reason, and high
Density lipoprotein dramatically increases, and the improvement of wherein high dose sample treatment group is best.
7 successive administration of table handles the influence to lipid of mice in 30 days
Note：There were significant differences for expression of the right shoulder of each column without identical lowercase, P<0.05.
8. the influence pair diabetes B mice serum glycated hemoglobin levels
Mouse glycosylated hemoglobin measurement result is as shown in table 8.Diabetes group mouse saccharification hemoglobin content is obviously high
In normally group mouse.After sample and positive drug are handled 30 days, low dosage, middle dosage, high dose and positive drug group saccharification
Hemoglobin level is significantly lower than diabetes group, and as sample dose increases, and glycosylated hemoglobin concentration reduces, and shows
Doses relationship.The ability that sample reduces glycosylated hemoglobin will be significantly better than positive drug processing group.
8 successive administration of table handles the influence to glycated hemoglobin levels in mice serum in 30 days
Note：There were significant differences for expression of the right shoulder of each column without identical lowercase, P<0.05.
9. the influence pair diabetes B mice serum inflammatory factor index
The results are shown in Table 9, compared with normally group mouse, inflammatory factor interleukin-6 in diabetes group mice serum
(IL-6), interleukin-1 ' beta ' (IL-1 β), tumor necrosis factor-alpha (TNF-α), endotoxin (LPS) it is horizontal it is all apparent on
It rises.After sample and positive drug continuous processing 30 days, inflammatory factor level decreased significantly in mice serum.
9 successive administration of table handles the influence to diabetes B mouse inflammatory factor in 30 days
Note：There were significant differences for expression of the right shoulder of each column without identical lowercase, P<0.05.
Three, analysis discusses
Streptozotocin (STZ) intraperitoneal injection structure diabetes B model mechanism of action is thin by inducing mouse pancreas islet β
Born of the same parents' necrosis, insulin secretion are reduced, to induced Diabetic.And diabetes remedy predominantly reduces blood glucose and improves pancreas islet
It is plain horizontal.
Solid beverage formula of the present invention contains alpha-glucosidase restrainer, can postpone carbohydrate absorption, reduces meal
Hyperglycemia afterwards.By mitigating the inhibition to insulin secretion, improves islet beta cell function, promote insulin secretion, while can have
Effect improves diabete peripheral herve pathology.
Experimental result shows that the solid beverage sample of positive drug and the present invention can significantly reduce diabetic mice on an empty stomach
Blood glucose level significantly improves serum insulin content, improves sugar tolerance and insulin tolerance, and can significantly improve diabetic mice
Blood lipids index.Comprehensive analysis, solid beverage sample blood sugar decreasing effect of the invention are better than positive drug.
Domestic and international numerous studies prove that serum free fatty acid increases when with diabetes, and serum free fatty acid and pancreas
Insulin resistance, diabetes B, Diabetic Macrovascular Complications, diabetic retinopathy are related.Research in recent years is it also holds that 2 types
Diabetes may be by cytokine mediated inflammatory reaction, be a kind of inborn immunity disease, inflammation is in diabetes B
Instrumentality is played in pathogenesis.In conclusion inflammatory factor IL-6, TNF-α and free fatty are diabetic neuropathies
Risk factor, therefore lower the level of free fatty acid and inflammatory factor through a variety of ways, diabetes may be delayed
Peripheral neuropathy.
Experimental result is shown, compared with diabetic mice, by the solid beverage sample treatment of positive drug and the present invention
Afterwards, serum free fatty acid, IL-6, TNF-α level significantly reduce, it may be possible to by reduce blood in serum free fatty acid,
IL-6, TNF-α concentration mitigate the inhibition to insulin secretion, improve islet beta cell function, to reach reduction hypoglycemic effect.
In addition, the group being divided into using above-mentioned experiment, has studied the solid beverage of embodiment 11 to diabetes B mouse liver
The influence of tissue fat denaturation, each group mouse liver HE coloration results are as shown in Figure 1.In Fig. 1：Blank group liver can under light microscopic
It is normal to see clearly lobuli hepatis structure.The arrangement of liver rope is close, using central vein as core radial arrangement around.Liver cell
Quantity is abundant, and in polygon, marshalling, cell color is deep, uniformly strong.There are one liver cell centers or multiple round cells
Core.The morphologic appearance of hepatic tissue is normal.And compared with blank control group, the lobuli hepatis structure for arriving diabetes group under the microscope is mixed
Disorderly, central vein deformation, liver rope broadening and it is disorganized.The compound oedema of swelling of liver cell, nucleus offset, endochylema are loose.It is small
Concentration, fragmentation or dissolving occur for the swelling of liver cell of mouse, part nucleus, filled with differing in size and a fairly large number of in cytoplasm
Round fat vacuole, liver cell are in serious diffusivity steatosis.More, volume that there are quantity in low dose group cytoplasm compared with
Big fat vacuole, illustrating the mouse liver tissue of low dose group, there are still more serious steatosises.Illustrate low dose group pair
The improvement result of diabetic mice hepatic steatosis is poor.Compared with diabetes group mouse, middle dose group is arrived under the microscope
Lobuli hepatis structure restores more apparent, and structural arrangement restores neat, and central vein restores ellipse, and liver rope, which narrows and arranges, is in
It is radial.Liver cell quantity is in polygon, marshalling compared with horn of plenty.Existing fat vacuole significantly reduces in cytoplasm.It says
Bright middle dose group has more apparent improvement result to diabetic mice hepatic steatosis.Compared with diabetes group mouse,
Under the microscope to the lobuli hepatis structure of high dose group obviously restore, central vein reverts to subcircular, and liver rope obviously narrows simultaneously
And arrangement show it is radial.Liver cell quantity is abundant, is in polygon, marshalling.Existing fat vacuole is bright in cytoplasm
It is aobvious to reduce, and almost without fat vacuole.Illustrate that high dose group has diabetic mice hepatic steatosis extremely significantly to change
Kind effect.Compared with diabetes group mouse liver, positive drug group liver cell quantity increases, and cell nucleus pyknosis weakens, but liver
There are still quantity in dirty tissue fat vacuole more, not of uniform size.This illustrates this group of adipose tissue, and there are a degree of fat
Fat is denaturalized, i.e. positive drug processing is weaker to the improvement result of diabetic mice hepatic steatosis.That is the solid of the embodiment
The processing of beverage high dose has the effect of most significant improvement diabetes B mouse liver steatosis.
Furthermore the group being divided into using above-mentioned experiment has studied the solid beverage of embodiment 11 to diabetes B mice pancreatic
The influence of form, each group mice pancreatic HE coloration results are as shown in Figure 2.In Fig. 2：The blank control group pancreas islet shape arrived under the microscope
Shape is subcircular, and pancreas islet edge clear is apparent, and island is regular, and islet cells is uniformly distributed and arranges close.Islet cells form
Full, quantity is more.This illustrates that normal state is presented in blank control group mouse pancreas islet.Diabetes group pancreas islet obviously wither by deformation
Contracting, pancreas islet blur margin are clear.Pancreas islet shape becomes irregular shape from circle, and islet cell mass significantly reduces, islet cells
Distribution is mixed and disorderly, cellular swelling, deformation, and endochylema is reduced, nucleus shrinkage.This explanation feeds 4 weeks plus the abdominal cavities STZ by high lipid food
Injection causes apparent damage to mouse islets.Compared with diabetes group mouse islets, the low dose group observed under light microscopic
Islet cells is less, and pancreas islet profile is unintelligible, and irregular shape is presented in pancreas islet.Islet cells is unevenly distributed, nucleus shrinkage.
This illustrates that low dosage processing to restoring pancreas islet form, promotes pancreas islet to restore poor with regenerated effect.With diabetes group mouse pancreas
Island is compared, and the islet cell mass showed increased for the middle dose group observed under light microscopic, pancreas islet volume becomes larger, island atrophy degree
There are improvement, pancreas islet form to revert to subcircular, pancreas islet edge becomes clear.Illustrate that middle dosage processing can be effectively improved repairing for pancreas islet
Multiple and regeneration.Compared with diabetes group mouse islets, the high dose group pancreas islet volume observed under light microscopic obviously becomes larger, and pancreas islet is thin
Born of the same parents' quantity is more abundant, and island atrophy degree is improved, and pancreas islet form reverts to subcircular, and pancreas islet edge becomes clear.Explanation
High dose processing can be effectively improved the reparation and regeneration of pancreas islet.Compared with diabetes group mouse islets, observed under light microscopic
The islet cell mass showed increased of positive drug processing group, pancreas islet volume become larger, and island atrophy degree has improvement, pancreas islet form
Subcircular is reverted to, pancreas islet edge becomes clear.Illustrate that positive drug processing can be effectively improved the reparation and regeneration of pancreas islet.I.e. originally
The obvious improvement diabetes B mouse of solid beverage middle dosage, high dose group and the positive drug group of embodiment energy
Islet function promotes it to repair and regenerate.
The foregoing is merely illustrative of the preferred embodiments of the present invention, is not intended to limit the invention, all essences in the present invention
All any modification, equivalent and improvement etc., should all be included in the protection scope of the present invention made by within refreshing and principle.
Claims (10)
1. a kind of solid beverage, which is characterized in that by the gross mass of the solid beverage be 100% in terms of, the solid beverage packet
Include the ingredient of following mass percentage：
2. solid beverage as described in claim 1, which is characterized in that the solid beverage includes following mass percentage
Ingredient：
3. solid beverage as described in claim 1, which is characterized in that the main active of the loquat-leaf extract is section
Roseau acid；And/or
The main active of the grape skin extract is resveratrol；And/or
The main active of the sweet tea extract is Rubusoside and sweet tea polysaccharide；And/or
The main active of the mulberry-leaf extract is 1-DNJ；And/or
The main active of the blue or green money willow extract is blue or green money willow polysaccharide and general flavone.
4. a kind of preparation method of solid beverage as described in any one of claims 1-3, which is characterized in that including walking as follows
Suddenly：
The green-tea extract, loquat-leaf extract, grape skin extract, sweet tea extract, mulberry-leaf extract and green money are provided
Willow extract；
By the green-tea extract, loquat-leaf extract, grape skin extract, sweet tea extract, mulberry-leaf extract and blue or green money willow
After extract carries out mixed processing, the first spray drying is carried out, the solid beverage is obtained.
5. preparation method as claimed in claim 4, which is characterized in that the mixed processing is at the first high pressure microjet crushing
Reason.
6. preparation method as claimed in claim 4, which is characterized in that it is described first spray drying condition include：Into wind-warm syndrome
103-107 DEG C of degree, 65-75 DEG C of temperature of outgoing air, 48-52 DEG C of tower wall temperature；And/or
Atomizer rotating speed 17000r/min.
7. such as claim 4 any one of them preparation method, which is characterized in that the preparation method packet of the green-tea extract
It includes：
Collect green tea；
After green tea water-removing, defibrination, the second high pressure microjet pulverization process is carried out, comminuting matter is obtained；
After the comminuting matter centrifugal filtration, the second spray drying is carried out, the green-tea extract is obtained.
8. preparation method as claimed in claim 7, which is characterized in that the rotating speed of the centrifugal filtration is 3000-5000r/min.
9. preparation method as claimed in claim 7, which is characterized in that it is described second spray drying condition include：Inlet air temperature
106-110 DEG C, 63-67 DEG C of temperature of outgoing air, 48-52 DEG C of tower wall temperature；And/or
Atomizer rotating speed 17000r/min.
10. such as claim 4-9 any one of them preparation methods, which is characterized in that in the step of described first is spray-dried
Later, further include the steps that In Aluminium Foil Packing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810245750.3A CN108324803A (en) | 2018-03-23 | 2018-03-23 | Solid beverage of auxiliary hyperglycemic and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810245750.3A CN108324803A (en) | 2018-03-23 | 2018-03-23 | Solid beverage of auxiliary hyperglycemic and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108324803A true CN108324803A (en) | 2018-07-27 |
Family
ID=62932293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810245750.3A Pending CN108324803A (en) | 2018-03-23 | 2018-03-23 | Solid beverage of auxiliary hyperglycemic and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108324803A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108853184A (en) * | 2018-08-31 | 2018-11-23 | 吉首大学 | A kind of blue or green money willow and Pasania cuspidata extract combination |
| CN112352895A (en) * | 2020-11-02 | 2021-02-12 | 辽宁康汇医学临床研究有限公司 | Angelica keiskei plant herbaceous solid beverage assisting in reducing blood sugar and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090099373A1 (en) * | 2000-08-31 | 2009-04-16 | Phenolics, Llc | Compositions enriched in anthocyanins |
| CN101709094A (en) * | 2009-12-17 | 2010-05-19 | 天津工业大学 | Method for separating sweet tea polysaccharide by ultrafiltration membranes |
| CN107455517A (en) * | 2017-08-24 | 2017-12-12 | 宣城华科宣木瓜生物科技有限公司 | A kind of mulberry leaf solid beverage and preparation method thereof |
-
2018
- 2018-03-23 CN CN201810245750.3A patent/CN108324803A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20090099373A1 (en) * | 2000-08-31 | 2009-04-16 | Phenolics, Llc | Compositions enriched in anthocyanins |
| CN101709094A (en) * | 2009-12-17 | 2010-05-19 | 天津工业大学 | Method for separating sweet tea polysaccharide by ultrafiltration membranes |
| CN107455517A (en) * | 2017-08-24 | 2017-12-12 | 宣城华科宣木瓜生物科技有限公司 | A kind of mulberry leaf solid beverage and preparation method thereof |
Non-Patent Citations (7)
| Title |
|---|
| 中医堂编委会: "《食物药效全典》", 31 January 2015, 黑龙江科学技术出版社 * |
| 刘娟: "青钱柳化学成分及药理活性研究进展", 《包头医学院学报》 * |
| 夏燕萍: "茶多酚改善代谢综合征大鼠糖脂代谢的作用机制研究", 《中国现代医学杂志》 * |
| 朱孝娟: "白藜芦醇对2型糖尿病大鼠血糖及血脂的影响", 《中华临床营养杂志》 * |
| 杨红霞: "《饮料加工技术》", 28 February 2015, 重庆大学出版社 * |
| 梅全喜: "《现代中药药理与临床应用手册》", 31 October 2016, 中国中医药出版社 * |
| 邓家刚: "《桂药原色图鉴》", 31 October 2008, 上海科学技术出版社 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108853184A (en) * | 2018-08-31 | 2018-11-23 | 吉首大学 | A kind of blue or green money willow and Pasania cuspidata extract combination |
| CN108853184B (en) * | 2018-08-31 | 2021-04-13 | 吉首大学 | Cyclocarya paliurus and lithocarpus polystachyus rehd extract composition |
| CN112352895A (en) * | 2020-11-02 | 2021-02-12 | 辽宁康汇医学临床研究有限公司 | Angelica keiskei plant herbaceous solid beverage assisting in reducing blood sugar and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN109549971A (en) | A kind of functional food and preparation method thereof adjusting hyperglycemia | |
| CN103536635A (en) | Preparation method of holothuria nobilis and application thereof in treatment of diabetes mellitus | |
| CN108771717A (en) | A kind of hypoglycemic health drink, preparation method and application | |
| CN105341893A (en) | Composition for assisting in reducing blood glucose and application | |
| CN104383259A (en) | Bitter gourd and mulberry leaf chromium-rich capsule and preparation method thereof | |
| CN108324803A (en) | Solid beverage of auxiliary hyperglycemic and preparation method thereof | |
| CN105030984A (en) | Lychee seed health oral liquid for reducing blood glucose, regulating blood lipid and relieving diabetic complications as well as preparation method of lychee seed health oral liquid | |
| CN106723029A (en) | A kind of health food and its preparation technology with auxiliary hyperglycemic function | |
| CN116531444B (en) | Cough-relieving lung-heat-clearing soft capsule and preparation process thereof | |
| CN106474083B (en) | Sweet Qi sugar is rather without sugar chawing tablet and its preparation process and application | |
| CN107156347A (en) | It is a kind of to be used for reducing blood lipid, health protection tea of blood pressure and preparation method thereof | |
| CN102579530A (en) | Preparation method of aralia taibaiensis total saponin having diabetes mellitus resisting effect and medicament | |
| CN103005436B (en) | Mulberry resource auxiliary blood sugar decreasing health food and preparation method thereof | |
| CN107468952A (en) | A kind of preparation method of the integration of drinking and medicinal herbs composition with auxiliary hyperglycemic function | |
| CN1872327B (en) | Composition of medicine for treating diarrhea | |
| CN114209758A (en) | Traditional Chinese medicine compound composition capable of maintaining blood sugar health level and preparation method and application thereof | |
| CN107095974A (en) | A kind of hypoglycemic composition | |
| CN1872232B (en) | Composition of medication for curing cerebrovascular disease, and preparation method | |
| KR20120089045A (en) | A composition comprising powder of amphicarpaea bracteata subsp.edgeworthii(benth.) h.ohashi and the extract thereof for preventing and treating diabetes mellitus and diabetic complication | |
| CN105031033B (en) | Blood sugar reducing pharmaceutical composition containing boxthorn leaves and preparation method and application thereof | |
| CN1872230B (en) | A medication for treating coronary heart disease and preparation method | |
| CN104940428B (en) | Hypoglycemic composition containing wolfberry fruits and application thereof | |
| CN1872231B (en) | Drop pills for treating diabetes, and preparation method | |
| CN107496510A (en) | A kind of blue or green money willow capsule and preparation method thereof | |
| CN109453249B (en) | Pharmaceutical composition for preventing and treating drug-induced liver injury and preparation method of different dosage forms |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180727 |
|
| RJ01 | Rejection of invention patent application after publication |